Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. reported the results of its 2026 annual shareholder meeting. Shareholders elected all seven director nominees and cast votes on 36,678,784 shares. They approved an amendment to the 2024 Omnibus Equity Incentive Plan to increase available shares and gave advisory approval to executive compensation.
Shareholders also advised holding future say-on-pay votes every one year and ratified Cherry Bekaert LLP as independent registered public accountants for the 2026 fiscal year. Overall, all management proposals received strong support.
KORU Medical Systems, Inc. Chief Technology Officer Eric Schiller purchased Common Stock in the open market. On May 18, 2026, he bought 5,000 shares at an average price of $3.9125 per share. Following this transaction, he directly owns 5,000 shares of KORU Medical Systems common stock.
KORU Medical Systems, Inc. CEO Linda M. Tharby bought additional company stock in the open market. On May 15, 2026, she purchased 1,191 shares of Common Stock at $3.92 per share. After this transaction, she directly owned 620,622 shares of KORU Medical common stock.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported an open-market purchase of 1,191 shares of the company’s Common Stock on May 15, 2026. After this transaction, she directly owns a total of 620,622 Common Stock shares.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported routine equity compensation activity. On May 14, she acquired 13,977 shares of common stock through the vesting of restricted stock units, while 7,326 shares were withheld at $3.94 per share to cover tax obligations.
KORU Medical Systems Chief Operating Officer Christopher Pazdan reported routine equity compensation activity. On the vesting of restricted stock units, he acquired 5,327 shares of common stock and 1,470 shares were withheld to satisfy tax obligations at a value of $3.94 per share. Following these transactions, he holds just over 310,000 shares directly.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan bought 5,000 shares of Common Stock in an open-market purchase at $3.88 per share. Following this transaction, he directly owns 305,131 shares.
KORU Medical Systems Chief Financial Officer Thomas Edward Adams reported routine equity compensation activity involving restricted stock units. On May 14, 2026, common stock was issued upon vesting of RSUs, each unit representing a contingent right to receive one share of common stock upon vesting.
In connection with this vesting, 2,900 shares of common stock were disposed of at $3.94 per share to satisfy tax obligations, while 8,193 shares were acquired through a derivative exercise/conversion. Following these transactions, Adams directly holds 316,340 shares of KORU Medical common stock. These are not open-market buy or sell transactions but compensation-related events.
KORU Medical Systems, Inc. Chief Financial Officer Thomas Edward Adams bought additional company stock in the open market. He purchased a total of 5,500 shares of common stock in two open-market transactions, paying $3.90 and $3.86 per share.